Evidence map›Paper›PMID 41847218›Full record

ArticleJournal of hepatocellular carcinoma2026

Microtubule-Associated Protein 4 Overexpression Correlates with Early Recurrence in Hepatitis B Virus-Associated Hepatocellular Carcinoma Patients Following Curative Hepatic Resection.

Yu-An Su, Yung-Tsung Li, Hui-Lin Wu, Jia-Horng Kao, Pei-Jer Chen, Chun-Jen Liu

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-An SuHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-4645-7121
Yung-Tsung LiHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Hui-Lin WuHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Jia-Horng KaoHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Pei-Jer ChenHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Chun-Jen LiuHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to investigate the clinical significance of MAP4 in hepatocellular carcinoma (HCC), particularly its association with metastasis-related early recurrence after curative hepatic resection. Patients and Methods: We enrolled 172 patients with hepatitis B virus-associated HCC (HBV-HCC) who underwent curative resection in our cohort. After excluding potential confounders such as vascular invasion and portal vein thrombosis, 101 patients were selected for MAP4 gene expression analysis by qRT-PCR. Kaplan-Meier and Cox regression analyses were conducted to evaluate its association with early recurrence and prognostic factors. Our findings were further validated in an independent cohort. Results: MAP4 expression was upregulated in HCC cell lines and tumor tissues, compared to their corresponding non-tumorous controls. The clinical analysis showed that high MAP4 overexpression in liver tumor tissues was positively correlated with early ( Conclusion: This study demonstrated that MAP4 overexpression in liver tumor tissue was positively correlated with early recurrence in HBV-HCC patients following curative hepatic resection, providing insights into its clinical significance and potential involvement in underlying molecular mechanisms, particularly in metastasis-related early recurrence.

Indexed as

curative hepatic resectionearly recurrenceHBV-HCChepatitis B virus-associated hepatocellular carcinomaMAP4metastasismicrotubule-associated protein 4

Identifiers

PMID41847218
PMCPMC12990817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.